Hashida Noriyasu, Hirose Rina, Shiozaki Daiki, Mamoto Yukinori
Ophthalmology, Osaka University, Suita, JPN.
Ophthalmology, Nakanoshima Eye Center Clinic, Osaka, JPN.
Cureus. 2024 Nov 22;16(11):e74268. doi: 10.7759/cureus.74268. eCollection 2024 Nov.
Allergic conjunctivitis (AC) is characterized by inflammatory responses in the conjunctiva and is often complicated by atopic dermatitis and mechanical irritation. Vernal keratoconjunctivitis (VKC), a severe subtype of AC, presents unique challenges in its diagnosis and management, particularly in pediatric patients. This case report describes an eight-year-old girl with VKC who exhibited poor adherence to a prescribed regimen of 0.05% epinastine ophthalmic solution and corticosteroid eye drops, resulting in persistent symptoms. Despite initial treatment, the patient's condition included giant papillae and thickened tarsal conjunctivae that were resistant to standard therapies. Upon transitioning to 0.5% epinastine eyelid cream, the patient showed improved adherence and partial symptom resolution. However, new limbal lesions, including Horner-Trantas dots, were observed following the cessation of steroid therapy. The reintroduction of steroids led to significant improvements in conjunctival lesions and complete resolution of limbal gelatinous hyperplasia. This case underscores the potential of epinastine eyelid cream in managing VKC, particularly in patients with adherence issues, and highlights the need for careful monitoring and combination therapy in severe cases. Further studies are needed to evaluate the long-term efficacy and safety of epinastine eyelid cream. However, once-daily application of eyelid cream may serve as a viable treatment and management option for pediatric patients with VKC.
过敏性结膜炎(AC)的特征是结膜发生炎症反应,常伴有特应性皮炎和机械性刺激。春季角结膜炎(VKC)是AC的一种严重亚型,在其诊断和治疗方面面临独特挑战,尤其是在儿科患者中。本病例报告描述了一名患有VKC的8岁女孩,她对规定的0.05%依匹斯汀眼药水和皮质类固醇眼药水治疗方案依从性差,导致症状持续。尽管进行了初始治疗,但患者的病情包括巨大乳头和睑结膜增厚,对标准治疗有抵抗性。改用0.5%依匹斯汀眼膏后,患者的依从性有所改善,症状部分缓解。然而,在停止使用类固醇治疗后,观察到新的角膜缘病变,包括赫纳-特兰塔斯点。重新使用类固醇导致结膜病变显著改善,角膜缘胶样增生完全消退。本病例强调了依匹斯汀眼膏在治疗VKC方面的潜力,特别是对于依从性差的患者,并突出了在严重病例中进行仔细监测和联合治疗的必要性。需要进一步研究来评估依匹斯汀眼膏的长期疗效和安全性。然而,对于患有VKC的儿科患者,每天一次涂抹眼膏可能是一种可行的治疗和管理选择。